Design of a compact superconducting accelerator for advanced heavy-ion therapy

Autor: Iwata, Y., Shirai, T., Mizushima, K., Matsuba, S., Yang, Y., Noda, E., Urata, M., Muramatsu, M., Katagiri, K., Yonai, S., Inaniwa, T., Sato, S., Abe, Y., Fujimoto, T., Sasano, T., Shiraishi, T., Suzuki, T., Takahashi, K., Kondo, Ki., Sakaki, H., Nishiuchi, M., Orikasa, T., Takayama, S., Amano, S., Nakanishi, K., Tachibana, M., Touchi, Y., Tsubomatsu, S., Nomura, S.

Publikováno v: In Nuclear Inst. and Methods in Physics Research, A August 2023 1053

Structural basis for hepatitis B virus restriction by a viral receptor homologue.

Autor: Shionoya K; Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan.; Graduate School of Science and Technology, Tokyo University of Science, Chiba, Japan.; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan., Park JH; Drug Design Laboratory, Graduate School of Medical Life Science, Yokohama City University, Kanagawa, Japan.; Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea., Ekimoto T; Computational Life Science Laboratory, Graduate School of Medical Life Science, Yokohama City University, Kanagawa, Japan., Takeuchi JS; Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan., Mifune J; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan., Morita T; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan., Ishimoto N; Drug Design Laboratory, Graduate School of Medical Life Science, Yokohama City University, Kanagawa, Japan., Umezawa H; Drug Design Laboratory, Graduate School of Medical Life Science, Yokohama City University, Kanagawa, Japan., Yamamoto K; Computational Life Science Laboratory, Graduate School of Medical Life Science, Yokohama City University, Kanagawa, Japan., Kobayashi C; Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan.; Graduate School of Science and Technology, Tokyo University of Science, Chiba, Japan.; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan., Kusunoki A; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan., Nomura N; Department of Cell Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Iwata S; Department of Cell Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.; RIKEN SPring-8 Center, Hyogo, Japan., Muramatsu M; Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan.; Department of Infectious Disease Research, Foundation for Biomedical Research and Innovation at Kobe, Hyogo, Japan., Tame JRH; Drug Design Laboratory, Graduate School of Medical Life Science, Yokohama City University, Kanagawa, Japan., Ikeguchi M; Computational Life Science Laboratory, Graduate School of Medical Life Science, Yokohama City University, Kanagawa, Japan.; HPC- and AI-driven Drug Development Platform Division, Center for Computational Science, RIKEN, Kanagawa, Japan., Park SY; Drug Design Laboratory, Graduate School of Medical Life Science, Yokohama City University, Kanagawa, Japan. park@yokohama-cu.ac.jp., Watashi K; Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan. kwatashi@niid.go.jp.; Graduate School of Science and Technology, Tokyo University of Science, Chiba, Japan. kwatashi@niid.go.jp.; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan. kwatashi@niid.go.jp.

Publikováno v: Nature communications [Nat Commun] 2024 Oct 25; Vol. 15 (1), pp. 9241. Date of Electronic Publication: 2024 Oct 25.

Anti-SARS-CoV-2 gapmer antisense oligonucleotides targeting the main protease region of viral RNA.

Autor: Yamasaki M; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan; Department of Virology II, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan; Department of Applied Biological Sciences, Tokyo University of Science, Noda, 278-8510, Japan., Saso W; Department of Virology II, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan., Yamamoto T; Infectious Diseases Unit, Tokushima Research Center for Drug Discovery, Otsuka Pharmaceutical Co., Ltd., Tokushima, 771-0192, Japan., Sato M; Infectious Diseases Unit, Tokushima Research Center for Drug Discovery, Otsuka Pharmaceutical Co., Ltd., Tokushima, 771-0192, Japan., Takagi H; Infectious Diseases Unit, Tokushima Research Center for Drug Discovery, Otsuka Pharmaceutical Co., Ltd., Tokushima, 771-0192, Japan., Hasegawa T; Department of Medicinal Chemistry, Tokushima Research Center for Drug Discovery, Otsuka Pharmaceutical Co., Ltd., Tokushima, 771-0192, Japan., Kozakura Y; Department of Drug Discovery Strategy, Office of Bioinformatics, Otsuka Pharmaceutical Co., Ltd., Tokushima, 771-0192, Japan., Yokoi H; Department of Drug Metabolism and Pharmacokinetics, Preclinical Research, Tokushima Research Center for Drug Discovery, Otsuka Pharmaceutical Co., Ltd., Tokushima, 771-0192, Japan., Ohashi H; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan., Tsuchimoto K; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan., Hashimoto R; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, 606-8507, Japan., Fukushi S; Department of Virology I, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan., Uda A; Department of Veterinary Science, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan., Muramatsu M; Department of Virology II, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan; Foundation for Biomedical Research and Innovation at Kobe, Institute of Biomedical Research and Innovation, Kobe, 650-0047, Japan., Takayama K; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, 606-8507, Japan., Maeda K; Department of Veterinary Science, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan., Takahashi Y; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan., Nagase T; Department of Medicinal Chemistry, Tokushima Research Center for Drug Discovery, Otsuka Pharmaceutical Co., Ltd., Tokushima, 771-0192, Japan., Watashi K; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan; Department of Virology II, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan; Department of Applied Biological Sciences, Tokyo University of Science, Noda, 278-8510, Japan; MIRAI, JST, Tokyo, 102-0076, Japan. Electronic address: kwatashi@niid.go.jp.

Publikováno v: Antiviral research [Antiviral Res] 2024 Oct; Vol. 230, pp. 105992. Date of Electronic Publication: 2024 Aug 23.

Status of the Bio-Nano electron cyclotron resonance ion source at Toyo University

Autor: Uchida, T., Minezaki, H., Ishihara, S., Muramatsu, M., Racz, R., Asaji, T., Kitagawa, A., Kato, Y., Biri, S., Drentje, A. G., Yoshida, Y.

In the paper, the material science experiments, carried out recently using the Bio-Nano electron cyclotron resonance ion source (ECRIS) at Toyo University, are reported. We have investigated several methods to synthesize endohedral C60 using ion-ion

Externí odkaz: http://arxiv.org/abs/1501.07024

Fullerene-rare gas mixed plasmas in an electron cyclotron resonance ion source

Autor: Asaji, T., Ohba, T., Uchida, T., Minezaki, H., Ishihara, S., Racz, R., Muramatsu, M., Biri, S., Kitagawa, A., Kato, Y., Yoshida, Y.

A synthesis technology of endohedral fullerenes such as Fe@C60 has developed with an electron cyclotron resonance (ECR) ion source. The production of N@C60 was reported. However, the yield was quite low, since most fullerene molecules were broken in

Externí odkaz: http://arxiv.org/abs/1501.07017